"Patients living with psoriatic arthritis often suffer from joint pain, stiffness and fatigue, impacting their ability to work and lead a physically active life," said Michael Severino, M.D., vice chairman and president, AbbVie. "The results of this large Phase 3 study further support the potential of RINVOQ to help these patients. We look forward to sharing these data with regulatory bodies around the world to support our application for label expansion for RINVOQ to include adult patients with active psoriatic arthritis."
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.